不同结石成分肝胆管结石病的临床病理特征与预后比较研究
本研究为回顾性队列研究,纳入353例肝胆管结石病患者,按结石成分分为胆固醇性(PCHL,n=35)、胆色素性(PBHL,n=241)和混合性(PMHL,n=77)三组。结果显示PCHL组腹痛、发热、黄疸发生率及肝脏萎缩、胆管扩张比例均显著低于PBHL和PMHL组,生化指标亦不同,治疗方式存在差异;PBHL与PMHL组表现相似。
要点
- 胆固醇性肝胆管结石患者腹痛、发热、黄疸发生率均低于胆色素性和混合性结石患者。
- 胆固醇性结石患者肝脏萎缩和胆管扩张比例低,谷氨酰转肽酶、碱性磷酸酶、总胆红素中位数较低。
- 胆固醇性结石患者血清白蛋白和胆固醇水平高于胆色素性结石患者。
核心结论
- 肝内胆固醇性结石患者与胆色素性、混合性结石患者在临床症状、影像学特征、生化指标和治疗方式上存在差异。
- 肝内胆色素性结石患者与混合性结石患者表现类似。
研究设计与样本
- 回顾性队列研究,收集2018年1月至2022年12月陆军军医大学第一附属医院两个院区肝胆外科连续收治的353例肝胆管结石病患者资料。
- 男性130例,女性223例,年龄(52.7±13.0)岁(范围:18~80岁)。
- 按结石成分分为胆固醇性结石组(n=35)、胆色素性结石组(n=241)和混合性结石组(n=77)。
主要发现
- PCHL组腹痛、发热、黄疸发生率分别为8.6%(3/35)、5.7%(2/35)、8.6%(3/35),均低于PBHL组[80.9%(195/241)、32.0%(77/241)、30.3%(73/241)]及PMHL组[76.6%(59/77)、27.3%(21/77)、24.7%(19/77)](P值均<0.017)。
- PCHL组肝脏萎缩和胆管扩张比例均为2.9%(1/35),低于PBHL组[39.8%(96/241)、91.3%(220/241)]和PMHL组[26.0%(20/77)、64.9%(50/77)](P值均<0.017)。
- PCHL组谷氨酰转肽酶、碱性磷酸酶、总胆红素中位数分别为82 U/L、105 U/L、12.9 μmol/L,均低于另外两组(P值均<0.017);血清白蛋白中位数42.9 g/L、胆固醇均值4.22 mmol/L,高于PBHL组(40.2 g/L、3.74 mmol/L)(P值均<0.017)。
- PCHL组中48.6%(17/35)接受肝部分切除术无胆肠吻合;PBHL组行肝切除及胆肠吻合的比例分别为72.6%(175/241)、43.2%(104/241);PMHL组为67.5%(52/77)、36.4%(28/77),差异均有统计学意义(P值均<0.017)。
临床怎么用
- 对于胆固醇性肝胆管结石患者,其临床症状和影像学表现较轻,可考虑以肝部分切除术为主而不行胆肠吻合。
- 胆色素性和混合性结石患者更常出现腹痛、发热、黄疸及肝脏萎缩、胆管扩张,且更多需要肝切除联合胆肠吻合。
- 术前可根据结石成分评估病情严重程度和手术方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical and pathological characteristics, surgical approaches, and prognosis of patients with hepatobiliary calculi of different stone compositions. Methods: This is a retrospective cohort study. Data were collected from 353 consecutive cases of hepatobiliary calculi patients admitted to the Departments of Hepatobiliary Surgery of the two campuses of the First Affiliated Hospital of Army Medical University from January 2018 to December 2022. The patients included 130 males and 223 females, with an age of (52.7±13.0)years(range:18 to 80 years). According to stone composition, patients were divided into a primary cholesterol hepatolithiasis (PCHL) group (n=35), a primary biliary hepatolithiasis (PBHL) group (n=241), and a primary mixed hepatolithiasis (PMHL) group (n=77). General data, clinical manifestations, imaging features, and biochemical indicators were collected for all three groups. Comparisons among the groups were performed using one-way ANOVA, Kruskal-Wallis H test, or χ2 test. For statistically significant data, post-hoc pairwise comparisons were conducted using Mann-Whitney U test, Fisher's exact probability method, or χ2 test. Results: Pairwise comparisons between groups revealed that the incidence rates of abdominal pain, fever, and jaundice in the PCHL group were 8.6% (3/35), 5.7% (2/35), and 8.6% (3/35), respectively, all significantly lower than those in the PBHL group (80.9% (195/241), 32.0% (77/241), 30.3% (73/241)) and the PMHL group (76.6% (59/77), 27.3% (21/77), 24.7% (19/77)) (all P<0.017). In terms of imaging features, the proportions of hepatic atrophy and bile duct dilation in the PCHL group were both 2.9% (1/35), significantly lower than those in the PBHL group (39.8% (96/241), 91.3% (220/241)) and the PMHL group (26.0% (20/77), 64.9% (50/77)) (all P<0.017). Laboratory findings: the medians of glutamyl transferase, alkaline phosphatase, and total bilirubin in the PCHL group were 82 U/L, 105 U/L, and 12.9 μmol/L, respectively, all significantly lower than those in the other two groups (all P<0.017). The median serum albumin and mean cholesterol levels in the PCHL group were 42.9 g/L and 4.22 mmol/L, respectively, higher than those in the PBHL group (40.2 g/L, 3.74 mmol/L) (all P<0.017). Treatment approaches:in the PCHL group, 48.6% (17/35) underwent partial hepatectomy without biliary-enteric anastomosis, while the rates for hepatectomy with biliary-enteric anastomosis were 72.6% (175/241) and 43.2% (104/241) in the PBHL group, respectively. The corresponding rates in the PMHL group were 67.5% (52/77) and 36.4% (28/77), with statistically significant differences (all P<0.017). Conclusion: Intrahepatic PCHL exhibits significant differences from PBHL and PMHL in clinical symptoms,imaging features,biochemical parameters and therapeutic strategies, whereas PBHL and PMHL exhibit similar characteristics. 目的: 探讨不同结石成分肝胆管结石病患者的临床和病理学特征、手术方式及预后情况。 方法: 本研究为回顾性队列研究。收集2018年1月至2022年12月陆军军医大学第一附属医院两个院区肝胆外科连续收治的353例肝胆管结石病患者的资料。男性130例,女性223例,年龄(52.7±13.0)岁(范围:18~80岁)。根据结石成分不同将患者分为胆固醇性结石(PCHL)组(n=35)、胆色素性结石(PBHL)组(n=241)及混合性结石(PMHL)组(n=77)。收集三组患者的一般资料、临床表现、影像学特点、生化指标等资料。三组间资料的比较采用单因素方差分析、Kruskal-Wallis H检验或χ2检验;将有统计学意义的资料进一步通过Mann-Whitney U检验、Fisher确切概率法或χ2检验行事后两两比较。 结果: 组间两两比较结果显示,PCHL组腹痛、发热、黄疸的发生率分别为8.6%(3/35)、5.7%(2/35)、8.6%(3/35),均低于PBHL组[80.9%(195/241)、32.0%(77/241)、30.3%(73/241)]及PMHL组[76.6%(59/77)、27.3%(21/77)、24.7%(19/77)](P值均<0.017)。影像学特征上,PCHL组肝脏萎缩和胆管扩张的比例均为2.9%(1/35),远低于PBHL组[39.8%(96/241)、91.3%(220/241)]和PMHL组[26.0%(20/77)、64.9%(50/77)](P值均<0.017)。实验室检查:PCHL组谷氨酰转肽酶、碱性磷酸酶、总胆红素的中位数分别为82 U/L、105 U/L、12.9 μmol/L,均低于另外两组(P值均<0.017);血清白蛋白的中位数42.9 g/L、胆固醇均值4.22 mmol/L,高于PBHL组(40.2 g/L、3.74 mmol/L)(P值均<0.017)。治疗方式:PCHL组中48.6%(17/35)接受肝部分切除术,无胆肠吻合;PBHL组行肝切除及胆肠吻合的比例分别为72.6%(175/241)、43.2%(104/241);PMHL组为67.5%(52/77)、36.4%(28/77),差异均有统计学意义(P值均<0.017)。 结论: 肝内PCHL患者与PBHL、PMHL患者在临床症状、影像学特征、生化指标、治疗方式等方面存在差异,而肝内PBHL患者与PMHL患者则表现类似。.
引用
- Yang X, Luo RH, Deng XM, et al. [Comparative study on the clinicopathological characteristics and prognosis of different types of hepatolithiasis]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41771529. doi:10.3760/cma.j.cn112139-20251101-00509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。